Nav: Home

Renoprotective effects of sglt2 inhibitors: Beyond glucose reabsorption inhibition

January 20, 2017

The clinical use of sodium glucose co-transporter 2 inhibitors (SGLT2) represents a recent advance in the treatment of diabetes. Accumulating evidence suggests that these drugs may reduce the risk for the development of diabetic nephropathy or reduce the rate of its progression in patients already suffering from this devastating complication. In this manuscript we summarize the available data on the mechanisms that underlie the renoprotective properties of SGLT2 inhibitors. Apart from their beneficial effects on carbohydrate and uric acid metabolism and their blood pressure-lowering properties, the most important mechanism that can explain the reduction in albuminuria and the preservation of renal function that follows their administration is the reduction in intraglomerular pressure. By increasing sodium delivery to the distal parts of the renal tubules, SGLT2 inhibition results in the vasoconstriction of the afferent arteriole thus reducing the intraglomerular pressure and the hyperfiltration that characterizes the early phases of diabetic nephropathy. In addition, the effect of SGLT-2 inhibitors on the renal and the systematic renin-angiotensin axis may also contribute to the observed renoprotection. More specifically, these drugs inhibit the renal renin-angiotensin axis due to increased delivery of sodium to the macula densa. Although the action of renin-angiotensin axis systematically increases, the concomitant use of drugs that modify the function of this system (angiotensin converting enzyme inhibitors and angiotensin receptor II antagonists), that is common in diabetic patients, results in the activation of type I angiotensin receptors that exhibits vasodilative, antiproliferative, antihypertrophic, and antinflammatory actions. Finally, it has been proposed that the reduction in the energy consumption in the proximal tubular cells as well as the shift in energy substrate utilization from glucose to ketone bodies may also increase the viability of renal tissues. In conclusion, SGLT2 inhibitors may represent the drugs of choice for the treatment and the prevention of diabetic nephropathy.
For more information about the article, please visit

Reference: Tsimihodimos, V., (2017). Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition. Current Vascular Pharmacology, DOI: 10.2174/1570161114666161007163426

Bentham Science Publishers

Related Glucose Articles:

Injectable solution may provide weeks of glucose control
Biomedical engineers at Duke University have created a biopolymer that can provide weeks of glucose control with a single injection.
Sugar sponges sop up and release glucose as needed
Many diabetes patients must inject themselves with insulin, sometimes several times a day, while others take medications orally to control blood sugar.
Not such a 'simple' sugar -- glucose may help fight cancer and inflammatory disease
Scientists have just discovered that glucose, the most important fuel used in our bodies, also plays a vital role in the immune response.
Convenient and easy to use glucose monitoring and maintenance
A research group from the Center for Nanoparticle Research within the Institute for Basic Science has developed a convenient and accurate sweat-based glucose monitoring and maintenance device.
How rare sugars might help control blood glucose
In an era when the label 'natural' hits a sweet spot with consumers, some uncommon sugars emerging on the market could live up to the connotation.
Neuronal stimulation regulates appetite and glucose levels in mice
This week in the JCI, a study led by Michael Scott at the University of Virginia explores how stimulation of a subset of neurons that produce glucagon-like peptides can control appetite and glucose levels in lean and obese mice.
Renoprotective effects of sglt2 inhibitors: Beyond glucose reabsorption inhibition
In this manuscript we summarize the available data on the mechanisms that underlie the renoprotective properties of SGLT2 inhibitors.
Mouse models indicate burning more fat and less glucose could lead to diabetes
Making muscles burn more fat and less glucose can increase exercise endurance, but could simultaneously cause diabetes, says a team of scientists from Baylor College of Medicine and other institutions.
Immune system uses gut bacteria to control glucose metabolism
Researchers have discovered an important link between the immune system, gut bacteria and glucose metabolism -- a 'cross-talk' and interaction that can lead to type 2 diabetes and metabolic syndrome when not functioning correctly.
Researchers discover new regulator in glucose metabolism
A key genetic switch in the liver regulates glucose metabolism and insulin action in other organs of the body.

Related Glucose Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...